Through Thick and Thin

Publisher Website
Google Scholar
Abstract
Two articles appear in this issue of the Journal that deal with apparently disparate topics. One, by Ponticelli and colleagues, describes the long-term outcome of an open, randomized, and prospective controlled trial of glucocorticoid combined with chlorambucil for the therapy of idiopathic membranous glomerulonephritis.1 The other, by Tiebosch and coworkers, describes the results of a prospective survey designed to evaluate the prevalence and clinical features of abnormal thinning of the glomerular basement membrane (thin-basement-membrane nephropathy) among patients undergoing renal biopsy for the investigation of idiopathic hematuria presumed to be of renal origin.2 Although superficially these topics may seem unrelated, they . . .